Core Viewpoint - The article discusses the upcoming IPOs of several companies, including CATL and Hengrui Medicine, highlighting their financial performance, market positioning, and investor interest. Group 1: CATL - CATL plans to list on the Hong Kong Stock Exchange on May 20, 2025, with the stock code "3570" [3] - The company aims to issue 117,894,500 H-shares, raising approximately HKD 30.718 billion (around USD 3.941 billion) at an issue price of HKD 263 per share [3] - This IPO will be the largest in Hong Kong since Kuaishou in 2021, with cornerstone investors committing a total of USD 2.628 billion [4] - As of December 31, 2024, CATL has equipped over 17 million electric vehicles with its batteries, capturing a significant market share [4] - The company has established partnerships with nine of the top ten global electric vehicle manufacturers and has seen revenue growth from CNY 328.6 billion in 2022 to CNY 362 billion in 2024 [5] Group 2: Hengrui Medicine - Hengrui Medicine is set to go public on May 23, 2025, under the stock code "1276" [7] - The company plans to issue 224,519,800 H-shares, potentially raising up to HKD 9.89 billion (approximately USD 1.267 billion) at a top-end price of HKD 44.05 per share [7] - Hengrui has attracted cornerstone investments totaling USD 533 million from major institutions, including GIC and Invesco [7] - The company has a diverse product portfolio, with 19 innovative drugs already on the market and over 90 in clinical or later stages [8] - Hengrui's revenue has grown from CNY 21.275 billion in 2022 to CNY 27.985 billion in 2024, with a compound annual growth rate of 14% since 2014 [10] Group 3: Mirxes - Mirxes has passed the hearing for its IPO and focuses on miRNA technology for disease screening solutions [13] - The company has commercialized its core product, GASTROClear™, for gastric cancer screening and has additional products in various stages of development [13][14] Group 4: Shouhui Group - Shouhui Group has also passed the hearing for its IPO and operates as an online insurance intermediary in China [16] - The company has established partnerships with over 110 insurance companies and has distributed more than 1,900 products since its inception [17] - Financially, Shouhui's revenue increased from CNY 806 million in 2022 to CNY 1.634 billion in 2023 [18] Group 5: Saint Bella - Saint Bella has received a notice for its overseas listing and operates a network of high-end confinement centers in China [19] - The company has expanded its services to include family care and women's health products, achieving significant revenue growth [20][21] - From 2021 to 2023, Saint Bella's revenue grew from CNY 259 million to CNY 560 million, with a notable increase in 2024 [21][22]

Core Viewpoint - Mirxes Holding Company Limited, known as "觅瑞," is a pioneer in developing and commercializing blood-based miRNA diagnostic kits for early cancer detection, with its core product GASTROClear™ being the only approved molecular diagnostic IVD product for gastric cancer screening globally [1][5]. Company Overview - Founded in 2014, Mirxes focuses on making disease screening and diagnostic solutions accessible in key Asian markets, including Singapore and China [2]. - The company has a core product, GASTROClear™, along with two other commercialized products (LungClear™ and Fortitude™) and six candidates in preclinical stages [4]. Product Details - GASTROClear™ consists of 12 miRNA biomarkers for gastric cancer screening and was successfully commercialized in Singapore after receiving regulatory approval in May 2019 [4]. - Fortitude™ 2.0 received temporary clinical use authorization in April 2020 and CE-IVD certification in June 2020, leading to its commercialization in Singapore and global markets [4]. - LungClear™ has been commercialized as an LDT service in Southeast Asia since December 2022 and in Japan since January 2023 [4]. Market Position - According to Frost & Sullivan, Mirxes is one of the few companies globally to have received regulatory approval for molecular cancer screening IVD products and is the only one for gastric cancer screening [5]. - The company has established end-to-end capabilities across research, clinical trials, production, and commercialization, with facilities in Southeast Asia, China, Japan, and the U.S. [5]. Team and Expertise - The founding team has significant academic achievements and research experience in miRNA molecular detection, having established Singapore's first RNA diagnostic PCR laboratory in the early 2000s [6]. - They founded a leading miRNA candidate discovery laboratory in Singapore in 2012, which had one of the highest throughput capacities globally [6]. Funding and Financial Strategy - Mirxes has received investments from notable institutions, including Rock Springs Capital and others, and secured $40 million in strategic financing from a fund under 康桥资本 to accelerate GASTROClear™'s market entry in the Asia-Pacific region [6][7]. - The net proceeds from the IPO will primarily fund the R&D, regulatory filings, production, and commercialization of GASTROClear™, as well as support ongoing and planned R&D efforts [7].

全球范围内首家且唯一一家获得分子胃癌筛查IVD产品监管批准的公司。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据 IPO 早 知 道 消 息 ， 中 国 证 监 会 国 际 合 作 司 于 2025 年 1 月 24 日 披 露 了 《 关 于 Mirxes Holding Company Limited（觅瑞集团控股有限公司，以下简称"觅瑞"）境外发行上市备案通知书》。 成立于2014年的觅瑞作为一家起源于新加坡的微小核糖核酸("miRNA")技术公司，中国总部在浙江 安吉，专注于在全球范围内普及疾病筛查诊断解决方案。 截至2024年10月31日，觅瑞拥有一种核心产品(即GASTROClear™)、两种其他商业化产品(即 LungClear™及Fortitude™)以及六种处于临床前阶段的候选产品。 其中，觅瑞的核心产品GASTROClear™为一个由12种miRNA生物标志物组成的用于胃癌筛查的基 于血液的miRNA检测组，其已于2019年5月获得新加坡卫生科学局的C类体外诊断证书后成功商业 化。 根据弗若斯特沙利文的资料，觅瑞是开发及商业化用于癌症及其他疾病 ...